Trastuzumab-Induced Cardiomyopathy. [Review]
Citation: Cardiology Clinics. 37(4):407-418, 2019 Nov.PMID: 31587782Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Breast Neoplasms/dt [Drug Therapy] | *Cardiomyopathies/ci [Chemically Induced] | *Trastuzumab/ae [Adverse Effects] | Antineoplastic Agents, Immunological/ae [Adverse Effects] | Cardiomyopathies/ep [Epidemiology] | Cardiotoxicity | Female | Global Health | Humans | IncidenceYear: 2019ISSN:- 0733-8651
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 31587782 | Available | 31587782 |
Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramatically improves HER2-positive breast cancer outcomes; however, its clinical use is associated with left ventricular dysfunction and heart failure. Patients receiving trastuzumab or other HER2-targeted therapies undergo routine cardiac function assessment. Holding and/or stopping trastuzumab treatment in the setting of left ventricular dysfunction is recommended. This article summarizes the role of trastuzumab in cancer treatment, the mechanisms of trastuzumab-induced cardiotoxicity, recent clinical investigations, and current controversies. Copyright (c) 2019 Elsevier Inc. All rights reserved.
English